TP53 and non-small cell lung carcinoma: In addition, a meta-analysis which analyzed 19 studies that involved 6,084 patients with NSCLC found the TP53 wild type was correlated with a remarkable higher overall survival (OS) than the TP53 mutant type (Gu et al. 2016).